Special Access Programs

Special Access Programs

Unlocking Global Access to Life-Changing Therapies

Medical innovation is moving faster than ever, yet regulatory delays and geographic boundaries often leave patients waiting. Septa exists to bridge the gap between scientific breakthrough and patient care.

We partner with pharmaceutical developers and healthcare networks to engineer compliant, scalable pathways that deliver medicines to those who need them most, regardless of borders.

Integrated Access Solutions

Effective access goes far beyond simple logistics. It requires mastering the intersection of complex regulations, clinical necessity, and international supply chains.

Assess & Strategize: Identify viable regulatory pathways while proactively managing compliance risks.

• Navigate Bureaucracy: Handle complex submissions and direct engagement with Health Canada and international bodies.

• Build Custom Programs: Design and launch bespoke access operational models tailored to your specific product.

• Safeguard the Chain: Manage the entire supply lifecycle, including rigorous pharmacovigilance and safety reporting.

• Accelerate Care: Prioritize speed and transparency to get treatments into physician hands without administrative bottlenecks.

Our Programs
Accesss Programs Eap
Expanded Access Programs (EAP)​

Facilitating pre-approval availability of investigational drugs for patients facing critical, life-threatening conditions outside of standard clinical trials.

Accesss Programs Post Trial
Post-Trial Continuity

Honoring commitments to clinical trial participants by maintaining their access to therapy between the study’s conclusion and commercial launch.

Accesss Programs Npp
Named Patient Programs (NPP)

Creating compliant pathways for patients to import medicines that are approved internationally but not yet commercially available in their home jurisdiction.

Accesss Programs Sap
Special Access Program (SAP)

Expert guidance through Canada’s specific regulatory mechanisms for unapproved drugs, ensuring seamless delivery to prescribing physicians.

accesss programs rwe
Real-World Evidence (RWE) Generation

Leveraging early access programs to capture critical safety and efficacy data that supports future regulatory approvals and reimbursement strategies.

Accesss Programs Market Commerical
Commercial Acceleration

Preparing the ground for market entry through early stakeholder mapping, pricing analysis, and phased rollout strategies.